The UAE Federal Decree-Law on Medical Products, Pharmacy Profession and Pharmaceutical Establishments (Federal Decree-Law No. 38 of 2024) officially entered into force on January 2, 2025, replacing the previously applicable Federal Law No. 8 of 2019. The Emirates Drug Establishment (EDE) is responsible for the federal-level regulation of medical products, including marketing authorization for medical devices, registration of manufacturing sites, product classification, and import and export permits.
It should be noted that this adjustment of regulatory functions does not mean that all functions of the Ministry of Health and Prevention (MOHAP) and the local health authorities of the individual emirates have been removed. Under Federal Decree-Law No. 38 of 2024, MOHAP and the local authorities continue to perform their respective duties in matters such as licensing of pharmaceutical professionals and local health regulation.
At present, services such as marketing authorization for medical devices should follow the current EDE service pages and the requirements of the EDE electronic platform. Based on the text of the federal decree-law, the current official EDE service pages and official documents published as of 2026, this article sets out answers to 20 frequently asked questions on UAE medical device market access.
Part 1: Regulatory Framework and Applicant Eligibility
Q1 Who approves medical devices in the UAE now? Does MOHAP still handle registration?
Answer: Federal-level marketing authorization for medical devices and related product regulatory services are handled by the EDE.
After Federal Decree-Law No. 38 of 2024 entered into force, matters such as product classification, marketing authorization, registration of manufacturing sites, product changes, renewals, import and export permits, and post-market surveillance for medical devices are processed under the current EDE regulatory system.
Companies applying for marketing authorization of a medical device should submit their application through the official EDE service portal and log in using UAE PASS as required by the platform.
However, this adjustment should not be understood as MOHAP and the local health authorities having completely withdrawn from the regulation of medical products. Licensing of pharmaceutical professionals and matters that local health authorities are legally responsible for should still be handled within their respective jurisdictions.
Practical advice: Do not continue to rely on the old MOHAP medical device registration process as the basis for current submissions. Before starting a project, first verify the corresponding EDE service page, applicant eligibility, and the latest platform requirements.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 1, 6 and 71; the current EDE marketing authorization service page for medical devices.
Q2 Which products count as medical devices in the UAE? Do software, AI and wearables qualify?
Answer: Software, AI products and wearable devices that meet the definition of a medical purpose can fall within the scope of medical device regulation, but a product should not be deemed a medical device merely because it uses AI or wearable technology.
Article 1 of Federal Decree-Law No. 38 of 2024 defines Medical Equipment as covering substances, devices, instruments, machinery, implants, detectors or systems, including accessories and the software required for their operation, and expressly mentions wearable devices and products based on artificial intelligence technologies.
Whether a product qualifies as medical equipment still needs to be assessed based on its intended use, mode of action, and whether it achieves the relevant medical purpose through non-pharmacological, non-immunological and non-metabolic means.
The main purposes listed in the law include:
- Diagnosis, treatment, cure, mitigation or prevention of disease, injury or disability;
- Detection, modification or replacement of an anatomical location; and
- Contraception.
Therefore, software as a medical device (SaMD), AI-assisted diagnostic software and smart monitoring devices with a medical intended use may fall within the regulatory scope. Ordinary health management software and consumer-grade smart wearables should not be deemed medical devices simply because they have monitoring functions.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 1 and 2.
Q3 Can a foreign manufacturer open an EDE account and submit the registration itself?
Answer: A foreign manufacturer cannot act directly as the applicant for UAE medical device marketing authorization based solely on its status as an overseas company.
Article 6 of Federal Decree-Law No. 38 of 2024 provides that applicants for marketing authorization should be pharmaceutical and medical product institutions licensed in the UAE. The entities listed in the law include:
- Licensed marketing offices (Marketing Office);
- Medical products manufacturers (Medical Products Manufacturer);
- Contracted medical products manufacturing companies (Contracted Medical Products Manufacturing Company); and
- Medical warehouses (Medical Warehouse) designated by the marketing rights holder.
In addition, the current EDE marketing authorization service page for medical devices explicitly states that the applicant should be a medical warehouse or marketing office holding a valid EDE license.
Therefore, foreign manufacturers generally need to complete product marketing authorization through a UAE-based entity that meets EDE requirements. The foreign legal manufacturer and its manufacturing site also need to complete the corresponding registration with the EDE.
Special note: There is a wording-level difference between the entities listed in Article 6 of the decree-law and the operating conditions on the current EDE medical device service pages. For projects planning to apply through a local manufacturer or contracted manufacturing company path, it is advisable to confirm the exact acceptance approach with the EDE before submission, rather than assuming the platform will definitely accept the application based only on the statutory list.
Legal basis: Federal Decree-Law No. 38 of 2024, Article 6; the EDE service page ‘Issuance of Marketing Authorization for a Medical Device’.
Q4 Who exactly is the MAH everyone talks about? Why do the terms often not match up?
Answer: It is necessary to distinguish between the marketing rights holder under the UAE decree-law, the MAH referred to on the EDE manufacturer registration page, and the local importer.
These entities bear different responsibilities.
| Entity | Meaning and main responsibilities |
|---|---|
| Marketing Rights Holder | The local legal entity that has obtained, under the decree-law, the right to market a specific medical product in the UAE; bears responsibility for product marketing, promotion and post-market follow-up |
| Legal Manufacturer | The manufacturer responsible for product design, manufacturing and the quality system; the EDE manufacturer registration service page requires the relevant legal manufacturers and manufacturing sites to complete registration |
| Importer | A local institution carrying out the import of medical products under an EDE license |
| Distributor | A local institution carrying out product distribution activities under a license |
| Main Pharmaceutical Establishment | The institution designated by the marketing rights holder under Article 22, responsible for product licensing matters, vigilance activities and full life-cycle management |
One point deserves particular attention: ‘Marketing Authorization Holder (legal manufacturer)’ as used on the EDE manufacturer registration page and ‘Marketing Rights Holder’ in the federal decree-law are not concepts that can be used interchangeably.
Contracts should separately specify the foreign manufacturer’s product responsibilities, the local marketing rights holder’s regulatory responsibilities, the importer’s import obligations, and the main pharmaceutical establishment’s post-market management responsibilities.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 1, 6, 21 and 22; the EDE service page ‘Registration of A Manufacturer of Medical Products’.
Q5 What preparatory steps must be completed before formally submitting a product registration?
Answer: The key items are product classification, registration of the manufacturer and manufacturing site, and licensing of the local entity.
Step 1: Product classification (applied for where needed).
If there is uncertainty about the nature of the product, its regulatory category, or whether a marketing authorization is required, a product classification letter can be requested from the EDE.
- Official service timeline: 10 working days;
- Official service fee: AED 500.
Classification is not a uniform prerequisite step that every product must apply for separately. For products whose nature is clear, whether a classification application should be submitted should be judged against the current EDE requirements.
Step 2: Complete the registration of the foreign legal manufacturer and its manufacturing site with the EDE.
The EDE marketing authorization page for medical devices explicitly requires that the manufacturing site of the product and the relevant MAH company be registered with the EDE before product registration.
Official service parameters for manufacturing site registration:
- Official timeline: 2-4 weeks;
- Application fee: AED 100;
- Registration fee: AED 10,000;
- Registration validity: 5 years, renewable upon expiry as required.
Step 3: Put in place the local entity and the import and distribution structure.
The local applicant entity must meet the EDE licensing requirements. For imported medical products, the importer, distributor and main pharmaceutical establishment structure required by Article 22 should also be planned in advance, so that the import channels are not found to be non-compliant only after the product has obtained marketing authorization.
The time needed for these items should not simply be added together as a fixed project timeline. Document legalization, entity licensing, document corrections and the specifics of the EDE review may all affect the actual progress.
Legal basis: The EDE service pages ‘Classification of a Medical Product’, ‘Registration of A Manufacturer of Medical Products’ and ‘Issuance of Marketing Authorization for a Medical Device’; Federal Decree-Law No. 38 of 2024, Articles 6 and 22.
Part 2: Registration Pathways and Technical Documentation
Q6 How many risk classes apply to medical devices in the UAE?
Answer: The EDE marketing authorization service page for medical devices uses a four-class system: Class I, II, III and IV.
The current EDE marketing authorization page for medical devices explicitly lists Class I, II, III and IV, and requires Class III and IV products to additionally submit safety and efficacy data.
Companies should determine the product class based on the intended use, working principle, mode of patient contact, duration of use and degree of risk of the product.
Regarding IVD products, some international harmonized systems use a four-tier risk classification of Class A, B, C and D. However, in the current EDE marketing authorization service page for medical devices reviewed for this article, no complete official public explanation was found that would confirm the UAE’s current IVD classification rules and their specific basis.
Therefore, it is not advisable to present the international IVD classification rules as the full set of official classification requirements explicitly adopted by the EDE. IVD projects should confirm the specific regulatory category and submission requirements through the EDE classification service.
Legal basis: The EDE service page ‘Issuance of Marketing Authorization for a Medical Device’; Federal Decree-Law No. 38 of 2024, Articles 1 and 6.
Q7 Is the classification letter only a reference opinion, or does it have actual effect?
Answer: The classification letter is an important written basis on which the EDE confirms the regulatory nature of a product.
The EDE classification service page explicitly states that the classification letter is mainly used to:
- Inform the applicant of the regulatory law applicable to the product in the UAE;
- Determine the regulatory category of the product and whether an EDE marketing authorization is required; and
- For products requiring a marketing authorization, complete the subsequent registration according to the category determined in the classification letter.
Therefore, companies should not presume the UAE classification directly from the registration class in other countries.
A classification application generally requires:
- Product catalogue and product photos;
- Proof of product status issued by the competent authority of the country of origin, such as a certificate of free sale or a registration certificate;
- Evidence of marketing in other countries, where available;
- Product description materials in English or Arabic;
- Artwork of the inner and outer packaging labels; and
- Product composition information, including a list of relevant ingredients or an MSDS where applicable.
Note that a classification letter is not equivalent to a marketing authorization; obtaining a classification result does not mean the product can already be imported and sold.
Legal basis: The EDE service page ‘Classification of a Medical Product’.
Q8 What exactly must be submitted for manufacturing site registration? ISO 13485 or GMP for devices?
Answer: For medical device manufacturing site registration, the focus should be on ISO 13485 and manufacturing license related documents, but site registration should not be conflated with all the quality requirements for product marketing authorization.
The main documents listed on the EDE manufacturing site registration service page for medical device manufacturing sites include:
- An authorization letter on the company’s official letterhead, notarized as required by the EDE;
- A valid and legalized ISO 13485 certificate;
- A valid business license or manufacturing license issued by the competent authority of the country of origin, authenticated as required by the EDE;
- A list of the medical products manufactured and/or assembled at the site; and
- A detailed company profile.
Two important distinctions apply here:
- Manufacturing site registration: The EDE medical device site registration checklist explicitly requires an ISO 13485 certificate;
- Product marketing authorization: Article 6(1)(f) of the decree-law separately requires a GMP certificate, involving a valid certificate issued by the EDE, the competent authority of the country of origin, or a reference authority recognized by the EDE.
Therefore, ISO 13485 and GMP should not simply be treated as fully equivalent, nor should completing site registration be taken to mean that all product-level quality requirements have been met.
In addition, the ISO 13485 certificate should not be broadly described as having to be issued by the competent authority of the country of origin. In practice, it should be prepared in accordance with the EDE’s requirements on certificate validity, legalization and recognition of the issuing body.
Legal basis: Federal Decree-Law No. 38 of 2024, Article 6(1)(f); the EDE service page ‘Registration of A Manufacturer of Medical Products’.
Q9 What is the core document checklist for product registration?
Answer: The documents listed on the EDE marketing authorization service page for medical devices can be grouped into the following five categories. Specific documents should be submitted according to the product class and the EDE’s review requirements.
| Document category | Main documents |
|---|---|
| Application and authorization | (1) Registration application form; (4) Copy of the product agency agreement |
| Entity qualification | (2) Valid manufacturing site registration certificate |
| Country-of-origin certificates | (3) Valid certificate of free sale/registration issued by the competent authority of the country of origin, authenticated by the UAE embassy as required |
| Conformity evidence | (5) Quality conformity certificate or marketing authorization, such as EC, 510(k), PMA, etc.; (11) Company declaration that the product conforms to the relevant specifications of the Medical Equipment Manual / EC-Declaration of Conformity |
| Product and technical documentation | (6) Post-market surveillance requirements; (7) Product description, composition, models, dimensions, accessories, intended use, contraindications, warnings, precautions and instructions for use, etc.; (8) Laboratory requirements, analytical data, and pricing information for certain devices; (9) Samples and certificates of analysis as required by product type; (10) Inner and outer packaging and product brochures; (12) Safety and efficacy data for Class III and IV products; (13) Special conformity certification for products of animal origin |
The following points deserve particular attention:
- The CFS or registration certificate must be issued by the competent authority of the country of origin and meet the EDE authentication requirements;
- EC, 510(k) and PMA are examples of conformity certificates listed on the EDE service pages; the applicable evidence should be determined by product classification;
- Samples, certificates of analysis and animal-origin material certificates should be prepared according to the product type and the EDE’s specific requirements;
- The EDE requires pricing information for some medical devices; the pricing requirement should not be understood as requiring the same pricing documents in the same format for all devices.
Legal basis: The EDE service page ‘Issuance of Marketing Authorization for a Medical Device’; Federal Decree-Law No. 38 of 2024, Article 20.
Q10 Can a product be registered in the UAE without CE or FDA?
Answer: The law does not make CE or FDA an absolute precondition for all medical devices, but the product must provide conformity evidence sufficient to support a marketing authorization.
Article 6(1)(c) of Federal Decree-Law No. 38 of 2024 provides that the EDE may assess a product based on the following evidence:
Pathway 1: Marketing authorizations and related assessment results from reference countries.
For example, if the product has already obtained a marketing authorization in a reference country, this can serve as important evidence of product conformity.
The conformity certificates listed on the current EDE service pages include EC, FDA 510(k), PMA and others.
Pathway 2: Research and technical documentation.
If the product does not have a marketing authorization from a relevant reference country, research data demonstrating the product’s effectiveness, safety in use and conformity with quality specifications can be provided, including applicable clinical evaluations and post-market data.
Note that Article 6 of the decree-law applies to different types of medical products; evidence such as clinical evaluations or pharmaceutical data should be selected according to the nature of the product, and bioequivalence data applicable to medicines should not be mechanically applied to ordinary medical devices.
Practical advice: Products that already hold CE or FDA related approvals generally find it easier to build a clear chain of conformity evidence; for products without such certificates, whether the EDE requirements can be met through other technical documentation should be assessed before the project starts.
Legal basis: Federal Decree-Law No. 38 of 2024, Article 6(1)(c); the EDE marketing authorization service page for medical devices.
Q11 Why do certificates of free sale (CFS) so often get rejected?
Answer: The key is that the issuing body and the authentication route must meet the EDE requirements.
The EDE marketing authorization service page for medical devices requires:
“A valid certificate of free sale/registration issued by the competent authorities in the country of origin certified by the UAE Embassy.”
In other words, the CFS or registration certificate should be issued by the competent authority of the country of origin and authenticated by the UAE embassy in that country as required by the EDE.
Common problems include:
- Non-compliant issuing body: Commercial certificates issued by chambers of commerce or industry associations cannot directly replace a certificate of free sale or registration issued by the competent authority;
- Non-compliant authentication route: Ordinary notarization or a single authentication step alone does not necessarily satisfy the EDE requirements;
- Non-compliant document status: Documents should be true, valid and consistent with the product being submitted.
The ISO 13485 certificate, business license and manufacturing license used for manufacturing site registration also need to be prepared in accordance with the legalization and authentication requirements of the corresponding EDE service pages.
The EDE public service pages do not set out a uniform validity period for CFS documents from all countries, nor do they require all authentications to be completed within the same timeframe. Therefore, the processing time of one project should not be treated as a uniform requirement for all countries.
Legal basis: The EDE service pages ‘Issuance of Marketing Authorization for a Medical Device’ and ‘Registration of A Manufacturer of Medical Products’.
Q12 What are the government fees and official timelines for UAE medical device registration?
Answer: According to the current public EDE service pages, the main fees and service timelines are as follows.
| Stage | Official service timeline | Government fees (AED) |
|---|---|---|
| Product classification (if applied for) | 10 working days | 500 |
| Medical device manufacturing site registration | 2-4 weeks | 100 application fee + 10,000 registration fee |
| Medical device marketing authorization | 45 working days | 100 application fee + 5,000 registration fee |
| Total (excluding classification) | – | 15,200 |
| Total (including classification) | – | 15,700 |
The above fees do not include local entity licensing, document notarization and authentication, translation, Arabic label adjustments, or local agency service fees.
There are separate fees for the import stage:
| Item | Official timeline / fee |
|---|---|
| Initial import application | 3 working days |
| Goods clearance application | 2 working days |
| Import permit application fee | AED 100 |
Points to note:
- AED 15,700 is not a fixed registration fee that all products must pay; AED 500 of it is incurred only when product classification is applied for separately;
- 45 working days is the service completion timeline published on the EDE marketing authorization service page for medical devices; it does not mean the whole project, from document preparation to actual market launch, takes only 45 working days;
- The import permit and the product marketing authorization are different procedures; import fees should not be mixed into product registration fees.
Legal basis: The EDE service pages ‘Classification of a Medical Product’, ‘Registration of A Manufacturer of Medical Products’, ‘Issuance of Marketing Authorization for a Medical Device’ and ‘Permit to Import Medical items and products’.
Part 3: Certificate Life-Cycle Management
Q13 How long is the registration certificate valid? When should renewal be started?
Answer: The marketing authorization for a medical device is valid for 5 years, and the renewal application should be submitted 90 days before the certificate expires.
Article 7 of Federal Decree-Law No. 38 of 2024 provides:
- The marketing authorization is valid for 5 years;
- It can be renewed for the same period;
- The renewal application should be submitted 90 days before expiry; and
- After the certificate expires, the activities permitted by the authorization should in principle not continue, unless the EDE determines or authorizes otherwise.
The parameters published on the current EDE medical device renewal service page are:
- Official service timeline: 15 working days;
- Application fee: AED 100;
- Renewal fee: AED 2,500.
Renewal generally requires the original product registration certificate, a valid manufacturing site registration certificate, a certificate of free sale/registration from the country of origin, approved certificates of minor changes (where any), conformity certificates and related declarations.
Special reminder: The fee item name on the EDE renewal service page still contains the wording ‘Renewal of the registration of pharmaceutical product for general sale’, which is not fully consistent with the medical device renewal service title. Although the page lists fees of AED 100 plus AED 2,500, companies should, when actually making payments, follow the fee items and payment notices generated by the EDE system.
Legal basis: Federal Decree-Law No. 38 of 2024, Article 7; the EDE service page ‘Renewal of Marketing Authorization for a Medical Device’.
Q14 Can the registration certificate be transferred? Can the local agent be changed?
Answer: Both can be handled in accordance with the law, but a distinction should be made between the transfer of ownership of a marketing authorization, a change of the marketing rights holder, and a change of importer.
Article 17(2) provides that, with EDE approval, ownership of a marketing authorization or conditional marketing authorization for a medical product may be transferred to another entity.
Article 16(3), by contrast, lists changes of the manufacturing location of a medical product and changes of the marketing rights holder among the matters that can be applied for as minor changes.
These two provisions should not be conflated:
- Transfer of ownership of a marketing authorization: EDE approval should be obtained under Article 17;
- Change of marketing rights holder: Handled under Article 16 and the current EDE change guidelines;
- Change of importer or distributor: Should be handled in light of Article 22 and the relevant EDE licensing and filing requirements, and should not be equated directly with a transfer of ownership of the marketing authorization.
Therefore, when changing a local partner, it is not enough to simply sign an agency termination agreement; the relationships between the original certificate holder, the new partner, the product marketing authorization and the import permit should also be confirmed, and the change procedures required by the EDE should be completed.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 16, 17, 22 and 33.
Q15 When does a design change, a site change or a label change require re-registration?
Answer: A distinction should be made between major changes that require a new marketing authorization application and matters that can be applied for as minor changes.
1. Situations requiring a new marketing authorization application (Article 15)
These mainly include:
- Substantial changes in product composition or formulation;
- Major changes in dosage form or concentration;
- Changes in product category or route of use that fall outside the scope of the original authorization;
- Major changes in the manufacturing process that may affect product quality, safety or efficacy;
- Fundamental changes in the design of a medical device;
- Reintroduction of a product, as a major change, after its voluntary withdrawal from the market;
- Major changes arising from pharmacovigilance results or new safety issues that require the product to be withdrawn or reassessed; and
- Other situations specified in the executive regulations.
2. Situations that can be applied for as minor changes (Article 16)
These mainly include:
- Minor changes in product composition, or the addition of new uses;
- Changes in the product’s external appearance or internal instructions;
- Changes in the product’s manufacturing location or marketing rights holder;
- Minor changes in the manufacturing method; and
- Other situations specified in the executive regulations.
Note that Article 16 of the decree-law refers to changes in the product’s external appearance or internal instructions; it does not mean that all changes to outer packaging, labels, models or product structure can be handled directly as minor changes.
The parameters published on the current EDE change service page are:
- Official service timeline: 22 working days;
- Official fee: AED 1,000.
In addition, the EDE explicitly states that, once a marketing authorization has expired, minor change applications are in principle no longer accepted unless a valid renewal application already exists.
Practical advice: Design changes, manufacturing site changes and label changes should first undergo a regulatory assessment. Before the corresponding approval is obtained, product information inconsistent with the approved documentation should not be used to supply products.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 15 and 16; the EDE service page ‘Issuance of a Certificate of Amendment to the Registered Marketing Authorization Data for a Medical Product’.
Q16 Can a product be appointed to only one agent?
Answer: For imported medical products subject to Article 22, the decree-law requires at least two import institutions to be appointed, with distribution institutions appointed separately.
Article 22(1) clearly provides that the marketing rights holder should:
- Appoint at least two licensed pharmaceutical and medical product institutions capable of carrying out import business as the product importers;
- Appoint one or more institutions licensed in the UAE to handle product distribution;
- Designate one main pharmaceutical establishment from the appointed institutions, responsible for product licensing matters, pharmacovigilance and full life-cycle management;
- Submit the marketing authorization application for each product uniformly through that main pharmaceutical establishment; and
- Ensure that all appointed institutions actually carry out the import of medical products within the calendar year.
On February 24, 2026, the EDE officially announced the launch of the multi-authorized-agent mechanism, expressly requiring companies to appoint more than one authorized agent for medical products placed on the UAE market, in order to reduce the supply risks of a single channel.
However, two exceptions deserve attention:
- Article 22(2) contains separate provisions on the storage and distribution arrangements for products manufactured locally in the UAE; and
- Article 22(4) allows the Cabinet, under prescribed procedures, to grant exemptions to marketing rights holders subject to Article 22.
Therefore, ‘at least two importers’ should not be simply understood as allowing no exceptions for any product under any circumstances.
Practical implications for Chinese manufacturers:
- Past cooperation structures with a single importer and a single agent need to be re-examined;
- The roles of the two importers and the distributors should be clearly specified separately in contracts;
- The main pharmaceutical establishment bears the responsibilities for the product’s marketing authorization and full life-cycle management; and
- A second importer should not be added only on paper without actually carrying out import business.
Legal basis: Federal Decree-Law No. 38 of 2024, Article 22; the EDE announcement on the multi-authorized-agent mechanism issued on February 24, 2026.
Part 4: Import and Post-Market Surveillance
Q17 Can goods be shipped as soon as the registration certificate is obtained?
Answer: No. The product marketing authorization and the import permit for each shipment are different procedures.
Article 31 provides that medical products and related raw materials for manufacturing may not be imported, exported or re-exported without EDE approval or a permit.
Article 32 further provides that an import permit must meet the corresponding conditions, including that the product to be imported already holds a valid EDE marketing authorization or emergency use authorization, or falls within the products exempted from marketing authorization by law.
The main requirements published on the current EDE import service page are as follows:
| Item | Official requirement |
|---|---|
| Initial import application | 3 working days |
| Goods clearance application | 2 working days |
| Application fee | AED 100 |
| Import permit validity | 2 months from the date of issuance |
| Importing entity | The product must be imported by the local agent named in the product marketing authorization |
| Initial import application documents | Each initial import application must be accompanied by one commercial invoice |
| Shelf life | Upon arrival at a UAE port, the remaining shelf life must not be less than two-thirds of the product’s total shelf life |
In addition:
- Multiple initial import applications under the same air waybill may, where EDE requirements are met, be consolidated for a goods clearance permit;
- Goods clearance requires electronic customs release and must, as required, be directed to a licensed medical warehouse;
- Arriving goods may be inspected by EDE inspectors;
- For products imported from certain closed free zones in the UAE, additional requirements such as a marketing office license and a Good Storage Practice (GSP) certificate issued by the EDE apply, and the shelf life of such products must not be less than 12 months;
- Radioactive materials must comply with the import permit requirements of the Federal Authority for Nuclear Regulation (FANR); and
- Relevant products containing animal-origin gelatin must, as required, be accompanied by a Certificate of Suitability issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM).
Conclusion: The product registration certificate addresses whether a product can obtain a marketing authorization in the UAE; the import permit addresses whether a specific shipment can be lawfully imported.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 31, 32 and 33; the EDE service page ‘Permit to Import Medical items and products’.
Q18 Within how many days must post-market adverse events for medical devices be reported?
Answer: Article 68 of Federal Decree-Law No. 38 of 2024 sets out the reporting timelines for serious incidents, non-serious incidents, product withdrawals and quality defects.
The main requirements are as follows:
- Serious adverse events and serious adverse reactions: Report as soon as possible after becoming aware, and in any case no later than 5 days;
- Follow-up reports on serious incidents: No later than 15 days;
- Non-serious adverse events: Submit a complete report within 90 days from the date of receipt of the relevant report;
- Complaints and reports on the withdrawal of a batch or an entire product: Report within 15 days from the date of awareness;
- Suspected counterfeit, falsified or illegal trading: Report immediately upon awareness;
- Product quality defects: Report within 15 days of receiving the complete relevant report.
Among these, the original text described all recall-related complaints as ‘immediate reporting’, which does not match the specific timelines in Article 68(3)(c) and should be corrected.
Regarding Decision No. 27 of 2026, a clear distinction is needed:
On July 27, 2026, the EDE published Decision No. 27, approving the ‘Guideline on Good Pharmacovigilance Practices for Medical Products’.
The guideline does indeed cover a risk management system (RMS), the master file of the national pharmacovigilance system (NPVSF), periodic safety update reports (PSUR), post-authorization safety studies (PASS), risk minimization measures and signal management.
However, the guideline explicitly excludes medical devices, veterinary medicines, medical products in clinical trials, and biological specimens stored in biobanks. Therefore, all the requirements of the guideline cannot be applied directly as mandatory requirements for the post-market pharmacovigilance system of medical devices.
Medical devices remain subject to the reporting obligations under Article 68 and to the specific regulatory requirements applicable to medical devices set by the EDE.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 21 and 68; EDE Board of Directors Decision No. 27 of 2026 and its ‘Guideline on Good Pharmacovigilance Practices for Medical Products’.
Q19 Does product promotion or exhibition marketing in the UAE require approval?
Answer: In principle, advertising, promotion and marketing of medical products require prior EDE approval.
Article 44 explicitly prohibits advertising, promoting or marketing medical products through visual, written, audio or social media means without EDE approval.
Article 45 provides that the main conditions for obtaining advertising approval include:
- The product already holds a valid EDE marketing authorization, except for products exempted by law;
- The applicant should be a licensed pharmaceutical or healthcare-related institution;
- The advertising content is true, not misleading, and supported by evidence;
- The advertising materials clearly disclose the relevant risks or side effects; and
- Other promotional requirements for different target audiences, such as professionals or the public, are met.
Article 46 further provides:
- Advertising approval is valid for between 30 days and 1 year; and
- Each medical product to be promoted must obtain its own separate advertising approval.
Companies should note:
Product brochures, clinical data promotional materials, exhibition posters and social media content should be assessed for EDE approval whenever they substantially constitute promotion of a medical product to the UAE market.
In addition, the participation of medical products in exhibitions or conferences should also take into account the dedicated licensing services the EDE has established for exhibition and conference participation; product advertising approval and exhibition participation permits should not be regarded as the same procedure.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 44, 45 and 46; the relevant EDE advertising and exhibition service pages.
Q20 What is the real cost of non-compliance?
Answer: Regulatory violations involving medical products in the UAE may result in criminal penalties, administrative regulatory measures, and revocation of marketing authorizations.
(1) Penalties for operating without a license and for products without a marketing authorization
Article 164(2) provides that violations of Article 5(1) (importing, distributing, holding, selling, displaying, re-marketing, using or manufacturing medical products without a marketing authorization, etc.) and Article 31(1) (importing or exporting medical products without approval or a permit), among others, may be punished with:
- Imprisonment of not less than 1 year and not more than 5 years;
- A fine of AED 100,000 to 500,000; or
- Either of the above penalties, or both.
(2) Penalties for submitting false documents
Article 164(1) provides that submitting forged or untrue documents, providing false information, or obtaining licenses through unlawful means may be punished with:
- Imprisonment of not less than 6 months and not more than 2 years;
- A fine of AED 50,000 to 200,000; or
- Either of the above penalties, or both.
(3) Penalties for advertising violations
Article 44 prohibits promoting medical products without EDE approval. Violations of Article 44 also fall under the penalties in Article 165, which provides for imprisonment of not less than 6 months and not more than 1 year and a fine of AED 50,000 to 200,000, or either of these penalties.
(4) Revocation of the product marketing authorization
Article 17 provides that the EDE may revoke a marketing authorization in the following situations:
- The product has been unavailable or absent from the market for two consecutive years after entering the market, without a reasonable justification accepted by the EDE;
- The marketing authorization was obtained on the basis of untrue documents;
- The product has been prohibited from manufacture, distribution or circulation in the UAE, in the country of origin, or by a reference authority recognized by the EDE;
- The manufacturer repeatedly fails to meet GMP or related storage and distribution requirements in a way that affects product quality;
- The product is proven to be unsafe, or repeatedly fails to meet the approved quality standards; or
- New safety issues arise that require the product to be withdrawn.
(5) The import permit may also be revoked
Article 33 provides that where a product’s marketing authorization has been revoked, product safety problems have arisen, or other statutory situations occur, the EDE may revoke the corresponding import, export or re-export permit.
The import permit itself may not be transferred. If the marketing rights holder or the import or export institution changes, the corresponding permits should be applied for again as required.
Legal basis: Federal Decree-Law No. 38 of 2024, Articles 5, 17, 31, 33, 44, 164 and 165.
Conclusion: The keys to UAE market access are the entity, the evidence and continuous compliance
Taken together, the 20 questions above show that UAE medical device market access requires close attention to three aspects.
First, the applicant entity and the import channels must meet local requirements.
Foreign manufacturers need to complete the corresponding EDE manufacturer and manufacturing site registrations and apply for marketing authorization through a qualifying local entity. For imported products subject to Article 22, at least two importers, one or more distribution institutions, and the responsibility arrangements for the main pharmaceutical establishment must also be put in place.
Second, the product technical documentation should correspond to the EDE’s actual submission requirements.
International market approvals such as CE and FDA can serve as conformity evidence, but they should not be treated as the only registration pathway for all products. Product classification, country-of-origin certificates, ISO 13485, conformity evidence, labeling and instructions, and post-market surveillance documentation should be prepared according to the product’s nature and the EDE’s requirements.
Third, compliance obligations continue after the registration certificate is obtained.
The 5-year validity of the registration, renewal 90 days before expiry, change approvals, import permits, vigilance reporting and the actual import obligations of multiple importers are all matters that require continuous management after a product enters the UAE market.
The 45 working days is only the service timeline published on the EDE marketing authorization service page for medical devices; it does not represent the full timeline from project launch to actual market launch. Companies should include entity registration, manufacturing site registration, document authentication, product submission and import preparation in a complete project plan.